Market cap
₹254 Cr
Recently Viewed
Clear AllMarket cap
₹254 Cr
Revenue (TTM)
₹545 Cr
P/E Ratio
30.9
P/B Ratio
2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹8 Cr
ROE
0.7 %
ROCE
1.4 %
Industry P/E
37.77
EV/EBITDA
18.3
Debt to Equity
0
Book Value
₹25.7
EPS
₹1.9
Face value
10
Shares outstanding
49,013,000
CFO
₹-30.84 Cr
EBITDA
₹20.56 Cr
Net Profit
₹-4.03 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Syschem (India)
| 10.8 | 20.3 | 9.0 | 23.4 | 10.7 | 51.4 | 25.5 |
|
BSE Healthcare
| 2.7 | 6.8 | 7.9 | 5.7 | 24.7 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Syschem (India)
| -5.3 | -1.4 | 18.2 | 179.2 | 127.1 | 5.6 | -36.3 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Syschem (India)
|
51.8 | 253.8 | 545.1 | 8.2 | 1.9 | 8.8 | 30.9 | 2.0 |
| 1,038.2 | 12,733.9 | 2,512.3 | 543.7 | 28.3 | 19.3 | 23.4 | 4.0 | |
| 444.6 | 7,694.1 | 1,053.1 | 293.6 | 32.3 | 24.6 | 26.2 | 5.9 | |
| 1,142.0 | 11,927.8 | 1,158.7 | 309.6 | 31.9 | 17.3 | 38.2 | 6.3 | |
| 1,680.1 | 31,850.1 | 8,850.1 | 894.8 | 15.2 | 19.8 | 36.6 | 6.4 | |
| 363.6 | 3,963.6 | 159.3 | 47.8 | 39.0 | 18.6 | 82.9 | 14.3 | |
| 15,003.0 | 19,243.2 | 1,575.1 | 179.1 | 14.9 | 11.4 | 107.4 | 11.6 | |
| 2,295.0 | 3,799.8 | 707.5 | 115.2 | 17.8 | 19.4 | 33 | -- | |
| 899.2 | 4,138.8 | 588.5 | 102.9 | 22.1 | 12.7 | 40.7 | 4.9 | |
| 211.9 | 5,585.6 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 8.4 |
No Review & Analysis are available.
Syschem (India) Limited manufactures and sells active pharmaceuticals ingredients (APIs), intermediates, bulk drugs, and specialty chemicals in India. Its APIs/intermediates include amoxycillin trihydrate, ampicillin trihydrate, cloxacillin sodium,... dicloxacillin sodium, flucloxacillin sodium, cephalexin, cefixime, and cefadroxil. The company also offers generic products in tablet, softgel/capsule, injection, syrup/suspension, and herbal and personal care forms. In addition, it engages in the distillation of specialty solvents, such as DMF, acetonitrile, ethyl acetate, and THF; and contract manufacturing business. The company was incorporated in 1993 and is based in Chandigarh, India. Read more
Incorporated
1993
Chairman
--
Managing Director
Ranjan Jain
Headquarters
Punchkula, Haryana
Website
Looking for more details about Syschem (India) Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsNo News & Announcements are available.
The share price of Syschem (India) Ltd is ₹51.78 (BSE) as of 30-Apr-2026 IST. Syschem (India) Ltd has given a return of 10.67% in the last 3 years.
The P/E ratio of Syschem (India) Ltd is 30.94 times as on 30-Apr-2026, a 18 discount to its peers’ median range of 37.77 times.
The P/B ratio of Syschem (India) Ltd is 2.01 times as on 30-Apr-2026, a 17 discount to its peers’ median range of 2.42 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
345.76
|
2.11
|
|
2024
|
86.73
|
4.20
|
|
2023
|
31.05
|
6.84
|
|
2022
|
0.00
|
4.43
|
|
2021
|
0.00
|
2.31
|
The 52-week high and low of Syschem (India) Ltd are Rs 62.00 and Rs 36.11 as of 30-Apr-2026.
Syschem (India) Ltd has a market capitalisation of ₹ 254 Cr as on 30-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Syschem (India) Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.